Book a Meeting

Anti-TRAIL-R4 Antibody, Non-Fucosylated (BioBet-1378ZP) (CAT#: BioBet-1378ZP) Datasheet

Target
TRAIL-R4
Isotype
Camel IgG
Description
Anti-TRAIL-R4 Antibody, Non-Fucosylated (BioBet-1378ZP) is a Camel monoclonal Camel IgG antibody against TRAIL-R4. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TRAIL-R4 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TNFRSF10D
Full Name
tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain
Background
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain, a transmembrane domain, and a truncated cytoplamic death domain. This receptor does not induce apoptosis, and has been shown to play an inhibitory role in TRAIL-induced cell apoptosis.
Alternative Names
TNFRSF10D; tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain; DCR2; CD264; TRUNDD; TRAILR4; TRAIL-R4; tumor necrosis factor receptor superfamily member 10D; TRAIL receptor 4; decoy receptor 2; TNF receptor-related receptor for TRAIL; TRAIL receptor with a truncated death domain; TNF-related apoptosis-inducing ligand receptor 4
Gene ID
8793
Cellular Localization
Membrane
Involvement in Disease
Diseases associated with TNFRSF10D include Osteogenic Sarcoma and Lung Cancer.
Related Pathways
Its related pathways are Cell surface interactions at the vascular wall and TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions.
Function
The receptor for cytotoxic ligands TRAIL. Contains a truncated death area, so it cannot induce apoptosis, but has a protective effect on mediated apoptosis. Reports on its ability to induce the nf-kpa-b pathway are contradictory. According to PubMed:9382840, it cannot, but according to PubMed:9430226, it can induce the nf-kpa-b pathway.
Field of research
Cancer antibody; Cell Biology and Cellular Response antibody; Cell Death antibody; Immune System antibody
Post-translational modifications
1.Glycosylation at Asn127 and Asn182 2.Modification sites at PhosphoSitePlus 3.Ubiquitination at Lys241
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Camel IgG
Antibody Clone
BioBet-1378ZP
Host
Camel
Species Reactivity
Human
Description
The anti-TRAIL-R4 antibody are useful in the treatment of various diseases and pathological conditions, including cancer.
Antibody Indication
Cancer

Cancer

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.